title: A pilot controlled trial of bupropion XL versus escitalopram in generalized anxiety disorder.
abstract: OBJECTIVE
  To compare the efficacy and safety of bupropion XL (150 to 300 mg/day) with the selective serotonin reuptake inhibitor escitalopram (10 to 20 mg/day) in outpatients diagnosed with generalized anxiety disorder (GAD).
  
  
  METHODS
  Twenty-four participants with GAD between 18 and 64 years enrolled in a 12-week, double-blind, randomized trial. The primary efficacy measures were the Clinical Global Impression of Improvement (CGI-I) and the Hamilton Anxiety Rating Scale (HARS).
  
  
  RESULTS
  Bupropion XL demonstrated comparable anxiolytic efficacy to escitalopram in outpatients with GAD. Both treatments were well-tolerated.
  
  
  CONCLUSIONS
  Findings from this pilot project suggest that bupropion XL may be useful in treating GAD. These preliminary results warrant further research to explore the use of bupropion XL in the treatment of GAD.
authors: Department of Psychiatry, University of California, Los Angeles, CA, USA. abystritsky@mednet.ucla.edu
authors: Alexander
authors: A
authors: Bystritsky
authors: Lauren
authors: L
authors: Kerwin
authors: Jamie D
authors: JD
authors: Feusner
authors: Tanya
authors: T
authors: Vapnik
mesh_terms: D000328:Adult; D018687:Antidepressive Agents, Second-Generation / Q000627:therapeutic use*; D001008:Anxiety Disorders / Q000188:drug therapy*; D016642:Bupropion / Q000627:therapeutic use*; D015283:Citalopram / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects
chemical_list: D018687:Antidepressive Agents, Second-Generation; D016642:Bupropion; D015283:Citalopram